文献速递内脏/肾动脉与血管畸形

下肠系膜动脉支架置入作为慢性肠系膜缺血的单血管治疗

Stenting of the Inferior Mesenteric Artery as a Single-Vessel Treatment for Chronic Mesenteric Ischemia.
PubMed 文献 · Ann Vasc Surg · 2026-10-05

该回顾性研究纳入2005至2025年间10例仅接受下肠系膜动脉(IMA)支架置入的症状性慢性肠系膜缺血(CMI)患者,技术成功率100%,全部患者症状即刻改善,随访期间无复发性肠系膜缺血症状。提示在特定临床和血管造影条件下,IMA单血管支架治疗安全可行。

要点

  • IMA单血管支架置入在严格选择的CMI患者中技术成功率高且症状改善明显。
  • 术后随访中所有患者均无复发性肠系膜缺血症状。
  • 需根据临床和血管造影条件审慎选择仅处理IMA的患者。

核心结论

  • 在特定临床和血管造影条件下,IMA单血管支架置入治疗CMI安全可行,短期和长期结果满意。

研究设计与样本

  • 回顾性综述,纳入2005至2025年间在本机构因症状性CMI仅接受IMA血管成形和支架置入的10例患者。

主要发现

  • 4例男性和6例女性,平均年龄68岁(范围50-85岁),均接受IMA单血管血管成形和支架置入。
  • 9例使用球囊扩张裸金属支架,1例使用药物洗脱支架,所有患者均有IMA严重狭窄。
  • 5例患者肠系膜上动脉(SMA)和腹腔动脉(CA)闭塞或严重狭窄,5例患者SMA和CA为非阻塞性病变。
  • 技术成功率为100%,所有患者CMI症状即刻临床改善。
  • 随访期0至10年,末次随访或死亡时所有患者均无复发性肠系膜缺血症状。

临床怎么用

  • 对于存在IMA严重狭窄且SMA/CA病变不适合或无需血运重建的CMI患者,可考虑IMA单血管支架置入。
  • 术后需长期随访以监测症状复发。

局限性

  • 样本量小(10例),为单中心回顾性研究,随访时间范围大(0至10年)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Angioplasty and stenting of the mesenteric arteries have increasingly become the first therapeutic option for chronic mesenteric ischemia (CMI). The superior mesenteric artery (SMA) and the celiac artery (CA) have been the usual targets for revascularization. However, published data on stenting of only the inferior mesenteric artery (IMA) for this disease are limited. This study evaluated the results in 10 patients treated at our institution. METHODS: This was a retrospective review of 10 patients who underwent angioplasty and stenting of only the IMA for symptomatic CMI from 2005 to 2025. Patient demographics, angiographic findings, procedural details, and outcomes were recorded. RESULTS: Four males and 6 females with a mean age of 68 years (range 50-85 years) underwent angioplasty and stenting of the IMA as a single vessel. Nine patients were treated with balloon-expandable bare metal stents. One was treated with a drug-eluting stent. All patients had critical IMA stenosis. Five patients had occlusions or critical stenosis of both the SMA and CA. Five patients had nonobstructive disease of the SMA and CA. Technical success was 100%, and immediate clinical improvement of CMI symptoms occurred in all patients. The follow-up period ranged from 0 to 10 years after the procedure. At their last follow-up or at the time of death, all patients remained free of recurrent mesenteric ischemic symptoms. CONCLUSION: Under certain clinical and angiographic situations, angioplasty and stenting of the IMA as a single vessel treatment can be safely performed in patients with CMI with satisfactory short- and long-term outcomes.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. El-Qawaqzeh K, Babu S, Goyal A, et al. Stenting of the Inferior Mesenteric Artery as a Single-Vessel Treatment for Chronic Mesenteric Ischemia. Ann Vasc Surg. 2026. PMID: 42833584. doi:10.1016/j.avsg.2026.09.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。